Advanced Search

Home > Journals > Minerva Ginecologica > Past Issues > Minerva Ginecologica 2016 August;68(4) > Minerva Ginecologica 2016 August;68(4):393-9

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUEMINERVA GINECOLOGICA

A Journal on Obstetrics and Gynecology

Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index

Frequency: Bi-Monthly

ISSN 0026-4784

Online ISSN 1827-1650

 

Minerva Ginecologica 2016 August;68(4):393-9

    ORIGINAL ARTICLES

A comparison between r-LH and urinary supplements containing LH activity in patients undergoing the microdose GnRH agonist flare protocol for in-vitro fertilization: a pilot study

Tal SHAVIT, Mohammed AGDI, Weon Y. SON, Josseph HASSON, Michael H. DAHAN

McGill Reproductive Center, McGill University, Royal Victoria Hospital, Montreal, Canada

BACKGROUND: The aim of this study was to compare pregnancy rates and stimulation parameters in patients with diminished ovarian reserve, who were treated with recombinant human luteinizing hormone (r-LH) or menopausal gonadotropins (hMG), as part of a microdose flare protocol.
METHODS: A retrospective cohort study was performed. Comparisons between the group that was stimulated with r-LH plus follicle stimulating hormone (FSH) to those treated with hMG and FSH, were performed. Measurements included: medication doses, number of oocyte collected, number of embryos obtained, pregnancy and clinical pregnancy rates.
RESULTS: Patients in the r-LH group (N.=40) had significant higher clinical pregnancy rates (33% vs. 14%; P=0.04) and used lower dose of LH (1938 IU vs. 2807 IU; P=0.02) compared to patients that were stimulated with hMG (N.=39).
CONCLUSIONS: r-LH may offer advantages for the treatment of diminished ovarian reserve when performing a microdose flare protocol when compared to hMG. Both larger and prospective studies should be carried out to confirm these findings.

language: English


FULL TEXT  REPRINTS

top of page